Glioblastoma atlas finds a recurring route between tumour cell states
An atlas of 12 primary glioblastomas found recurring changes in cancer cell states across different tumour regions. Genetic differences did not divide those states into separate, neatly bounded groups. The peer-reviewed findings help describe how much diversity a single biopsy can miss, while laboratory observations support a proposed trajectory without establishing a treatment benefit.
Science··Evening
A tumour atlas maps recurring cell states
Cancer cells in glioblastoma, an aggressive brain tumour, occupy different states and can change their characteristics. A new atlas found recurring patterns in those states and their arrangement within tumour tissue. The peer-reviewed work, published on 4 November, connects cellular diversity with a proposed trajectory of change, offering a framework for understanding the internal variety that complicates the disease.[1], [2]
The atlas covers 57 sampled regions from 12 primary tumours. Information from more than one million cell nuclei was combined with tissue maps showing where genes were active. Linking those layers allowed the team to compare what a cell was like with where it sat. The samples came from patients undergoing surgery at Cambridge University Hospitals in Britain, with consent and ethical approval.[1]
Genetic groups intermingle across the tissue
The recurring path runs from states resembling developing neural precursors toward states associated with glial injury responses and a shortage of oxygen. These states have a spatial organization across the tissue. Eight of the 12 tumours contained nearly the full set of core tissue microenvironments, while independent pathology assessments helped identify the anatomical regions. The different states therefore occur within a structured tissue landscape.[1]
Genetically distinct subgroups of cancer cells were finely mixed together. Each subgroup could contain several cellular states rather than belonging to just one. This complicates any classification that treats a tumour as a single uniform population. A biopsy from one location can capture only part of its cellular landscape, because other regions can contain a different balance of states.[1]
Laboratory observations support the proposed trajectory
Relationships inferred from mutations and observations in patient-derived organoids supported the proposed path. Organoids are laboratory models made from patients’ tumour cells. The observations followed changing cell populations over time, without continuously tracking every individual cell’s lineage. Whether cells can fully reverse along the path remains unresolved. Surrounding immune-cell signals were associated with parts of it, while the complete set of directing factors is unknown. No treatment was tested for clinical benefit in this atlas study.[1]
